Deferiprone NDC 75907-349

NDC codes

FDA NDC Directory

Product NDC (as listed)75907-349Labeler and product segments. Claims need a package NDC.

Product NDC at billing width75907-0349Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
75907-349-01	75907034901	100 TABLET, COATED in 1 BOTTLE (75907-349-01)Marketed from Dec 15, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Deferiprone
Generic name (nonproprietary): deferiprone
Active ingredients: Deferiprone — 500 mg/1
Dosage form: Tablet, Coated
Route: Oral
Labeler: DR. REDDY'S LABORATORIES, INC.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 220132
Marketing start: Dec 15, 2025
Listing expires: Dec 31, 2026
Other FDA classes: Iron Chelating Activity (Mechanism)
Identifiers: Product ID 75907-349_c3247274-c72a-4181-9638-58f7ff14729cSPL ID c3247274-c72a-4181-9638-58f7ff14729cSPL set ID 67139215-1154-4e1a-ae15-0f3cd8af5177RxCUI 389242, 2180997UNII 2BTY8KH53LUPC 0375907349010, 0375907348501
Pharmacologic class: Iron Chelator

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N475907034901 followed by a unit qualifier and the quantity

Package 75907-0349-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 15, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Deferiprone tablets are indicated for the treatment of transfusional iron overload in adult patients with thalassemia syndromes when current chelation therapy is inadequate. Limitations of Use Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or in patients with Diamond Blackfan anemia. Pediatric use information is approved for Chiesi USA, Inc.'s FERRIPROX® (deferiprone) tablets. However, due to Chiesi USA, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information. Deferiprone tablets are an iron chelator indicated for the treatment of transfusional iron overload in a…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 220132

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 220132
Product	Strength	Form · route	Labeler	Product NDC
Deferiprone	Deferiprone 1000 mg/1	Tablet, CoatedOral	DR. REDDY'S LABORATORIES, INC.	75907-348